Astellas Pharma to buy Audentes Therapeutics for $3bn

This article was originally published here

Under the deal, Astellas US Holding wholly-owned subsidiary Asilomar Acquisition will acquire Audentes by paying $60 per share in cash. Audentes chairman and CEO Matthew Patterson said: “With

The post Astellas Pharma to buy Audentes Therapeutics for $3bn appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply